Palatin Technologies, Inc
12
0
2
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
16.7%
2 terminated/withdrawn out of 12 trials
80.0%
-6.5% vs industry average
25%
3 trials in Phase 3/4
50%
4 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects
Role: lead
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
Role: lead
Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)
Role: lead
A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye
Role: lead
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
Role: lead
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Role: lead
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Role: lead
Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye
Role: collaborator
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
Role: lead
Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma
Role: lead
Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension
Role: lead
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
Role: lead
All 12 trials loaded